5 patents currently held
32 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Feb 2027. from the record
Of the 32 now held by other companies, 12 were conveyed to Epizyme Inc. in the filing they arrived in, and 20 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Feb 2027
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2028 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Oct 2029 · High confidence
Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf
US 7,741,450
The most cited patent in this portfolio, cited by 33 later US patents, top 25% of utility patents granted in 2010 in our data. Protection runs to 2028.
Chlorotoxin Polypeptides and Conjugates and Uses Thereof
US 9,018,347
Cited by 24 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Multikinase Inhibitors for Use in the Treatment of Cancer
US 8,609,640
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2029.
Formerly held, still cited
Notable
Ends Aug 2034 · High confidence
The most cited patent in this portfolio, cited by 138 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2034.
conveyed to Eisai R and D Mangement Co. Ltd. - now held by Epizyme, Inc.
Also notable
Ends Aug 2030 · High confidence
Cited by 58 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
now held by Taiho Pharmaceutical Co., Ltd.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 2 terms have ended since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf | 3 in force | to Feb 2028 |
| Chlorotoxin Polypeptides and Conjugates and Uses Thereof | 1 in force | to Feb 2031 |
| Multikinase Inhibitors for Use in the Treatment of Cancer | 1 in force | to Oct 2029 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,422,367 | Antigenic GM-CSF Peptides and Antibodies to GM-CSF In force · High confidence | In force | High confidence | |
| US 8,318,168 | Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf In force · High confidence | In force | High confidence | |
| US 7,741,450 | Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf In force · High confidence | In force | High confidence | |
| US 8,609,640 | Multikinase Inhibitors for Use in the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 9,018,347 | Chlorotoxin Polypeptides and Conjugates and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 32 patents in force now held by others · 207 patents ended · 2 applications pending · 135 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.